 |
|
UV light improving chances of fighting cancer
October 30, 2007Light-activated antibodies
Scientists at Newcastle University have developed a cancer fighting technology which uses UV light to activate antibodies which very specifically attack tumours.
Therapeutic antibodies have long been recognised as having excellent potential but getting them to efficiently target tumour cells has proved to be very difficult.
Now, Professor Colin Self and Dr Stephen Thompson from Newcastle University have developed a procedure to cloak antibodies which can then be activated by UV-A light and so can be targeted to a specific area of the body just by shining a probe at the relevant part.
This procedure maximizes the destruction of the tumour while minimising damage to healthy tissue.
Professor Self says, "I would describe this development as the equivalent of ultra-specific magic bullets. This could mean that a patient coming in for treatment of bladder cancer would receive an injection of the cloaked antibodies. She would sit in the waiting room for an hour and then come back in for treatment by light. Just a few minutes of the light therapy directed at the region of the tumour would activate the T-cells causing her body's own immune system to attack the tumour."
The details are contained in two papers* published online today in the journal ChemMedChem.
The Newcastle University researchers demonstrate in the first paper the procedure of coating the surface of a protein, such as an antibody, with an organic oil which is photocleavable, a process called "cloaking". This prevents the antibody reacting within the body unless it is illuminated.
When UV-A light is shone onto the cloaked antibody it is activated. The activated antibody binds to T-cells, the body's own defence system, triggering the T-cells to target the surrounding tissue.
In the second paper, they demonstrate that when the cloaked antibodies are activated by light near a tumour, the tumour is killed. This work means that antibodies can be targeted to kill cancer tumours with much greater specificity giving fewer side effects.
These cloaked antibodies can be used alone, or in conjunction with the many antibodies already produced against a wide variety of cancers as bispecific complexes. These complexes are formed from two antibodies, one antibody binds to a tumour marker, the other with a T-cell. The T-cell binding end remains inactive until re-activated by light. This means when the bispecific antibody binds to healthy tissues away from light, it cannot activate T-cells, resulting in far fewer side effects.
Professor Self says, "This opens up so many possible applications for example, for patients who are undergoing surgery for prostate cancer. After the surgeon has removed the bulk of a tumour, the patient could then be injected with bispecific antibodies and a light shone at the affected area which would target the patient's own immune system to the tumour site."
"This is therefore a very specific treatment and while our work indicates that sunlight doesn't activate these antibodies, patients may have to be advised to avoid direct sunlight for a short period after treatment."
Newcastle University
Now, Professor Colin Self and Dr Stephen Thompson from Newcastle University have developed a procedure to cloak antibodies which can then be activated by UV-A light and so can be targeted to a specific area of the body just by shining a probe at the relevant part.
This procedure maximizes the destruction of the tumour while minimising damage to healthy tissue.
Professor Self says, "I would describe this development as the equivalent of ultra-specific magic bullets. This could mean that a patient coming in for treatment of bladder cancer would receive an injection of the cloaked antibodies. She would sit in the waiting room for an hour and then come back in for treatment by light. Just a few minutes of the light therapy directed at the region of the tumour would activate the T-cells causing her body's own immune system to attack the tumour."
The details are contained in two papers* published online today in the journal ChemMedChem.
The Newcastle University researchers demonstrate in the first paper the procedure of coating the surface of a protein, such as an antibody, with an organic oil which is photocleavable, a process called "cloaking". This prevents the antibody reacting within the body unless it is illuminated.
When UV-A light is shone onto the cloaked antibody it is activated. The activated antibody binds to T-cells, the body's own defence system, triggering the T-cells to target the surrounding tissue.
In the second paper, they demonstrate that when the cloaked antibodies are activated by light near a tumour, the tumour is killed. This work means that antibodies can be targeted to kill cancer tumours with much greater specificity giving fewer side effects.
These cloaked antibodies can be used alone, or in conjunction with the many antibodies already produced against a wide variety of cancers as bispecific complexes. These complexes are formed from two antibodies, one antibody binds to a tumour marker, the other with a T-cell. The T-cell binding end remains inactive until re-activated by light. This means when the bispecific antibody binds to healthy tissues away from light, it cannot activate T-cells, resulting in far fewer side effects.
Professor Self says, "This opens up so many possible applications for example, for patients who are undergoing surgery for prostate cancer. After the surgeon has removed the bulk of a tumour, the patient could then be injected with bispecific antibodies and a light shone at the affected area which would target the patient's own immune system to the tumour site."
"This is therefore a very specific treatment and while our work indicates that sunlight doesn't activate these antibodies, patients may have to be advised to avoid direct sunlight for a short period after treatment."
Newcastle University
Antibody Current Events and Antibody News RSSRNA molecules, delivery system improve vaccine responses, effectiveness
A novel delivery system that could lead to more efficient and more disease-specific vaccines against infectious diseases has been developed by biomedical engineers at The University of Texas at Austin.
What is the influence of tumor removal on the serum level of carbohydrate's antibody?
Cancer immune surveillance is considered to be important in the anti-tumor protection of the host. The growing tumor escapes the immune control under the immunosuppressive conditions.
Nanodiamond drug device could transform cancer treatment
A Northwestern University research team has developed a promising nanomaterial-based biomedical device that could be used to deliver chemotherapy drugs locally to sites where cancerous tumors have been surgically removed.
Children's National researchers develop novel anti-tumor vaccine
A novel anti-tumor vaccine for neuroblastoma and melanoma developed by scientists and clinicians at Children's National Medical Center in collaboration with investigators from the University of Iowa is showing significant impact on tumor growth in mice.
Advance offers revolution in food safety testing
Microbiologists at Oregon State University have developed a new technology to detect illness-causing bacteria - an advance that could revolutionize the food industry, improving the actual protection to consumers while avoiding the costly waste and massive recalls of products that are suspected of bacterial contamination but are perfectly safe.
New technique sees into tissue at greater depth, resolution
By coupling a kicked-up version of microscopy with miniscule particles of gold, Duke University scientists are now able to peer so deep into living tissue that they can see molecules interacting.
New results help predict treatment response in colorectal cancer
Genetic testing can identify a group of patients with advanced colorectal cancer who are likely to survive on average twice as long if treated with the drug cetuximab, late breaking results show.
Wistar researchers invigorate 'exhausted' immune cells
In battles against chronic infections, the body's key immune cells often become exhausted and ineffective. Researchers at The Wistar Institute have found a way to restore vigor to these killer T cells by blocking a key receptor on their surface, findings that may advance the development of new therapies for diseases such as HIV, hepatitis B and C, and cancer.
Which is more accurate, serology test or C14-urea breath test?
Serology and C14-UBT are the most commonly used non-invasive tests of H. pylori infection. The diagnostic characteristics of the tests depend also on the prevalence of H. pylori infection in the population tested.
M. D. Anderson study finds change in HER2 status after treatment with Herceptin
Researchers at The University of Texas M. D. Anderson Cancer Center have discovered that when treated with Herceptin prior to surgery, 50 percent of HER2 positive, breast cancer patients showed no signs of disease at the time of surgery.
More Antibody Current Events and Antibody News Articles
 | Antibodies: A Laboratory Manual by Ed Harlow, David Lane Introduction to immunochemistry for molecular biologists and other nonspecialists.... |
 | Antibody Engineering: Methods and Protocols (Methods in Molecular Biology) (Methods in Molecular Biology) A core collection of diverse cutting-edge techniques for the generation, expression, optimization, and characterization of recombinant antibodies. Readily reproducible protocols for lead generation range from the cloning of human immunoglobulin genes to the selection and generation of human recombinant antibodies by humanization approaches, molecular display technologies and transgenic animals.... |
 | Handbook of Therapeutic Antibodies 3-Volume Set In this most comprehensive reference source for the development, production and therapeutic application of antibodies, Volume I contains general chapters presenting established technologies and clinical applications. Volume II provides a look at emerging technologies, new therapeutic concepts, and clinical studies. The third volume features detailed and specific information about each currently... |
 | Monoclonal Antibodies: Methods and Protocols (Methods in Molecular Biology) Monoclonal Antibodies: Methods and Protocols examines a collection of state-of-the-art methods that employ monoclonal antibodies in a clinical setting with opening chapters focusing on the gold standard method for generating mouse monoclonal antibodies through hybridoma technology, future methods for engineering recombinant and humanized antibodies, methods for engineering soluble Fc fusion... |
 | Basic Methods in Antibody Production and Characterization Written for researchers and professionals in the fields of biomedical research, immunology, biochemistry, molecular biology, pathology, and biotechnology, Basic Methods in Antibody Production and Characterization uses a cookbook approach to presenting the methods for the production, characterization, and use of antibodies. Antibodies described include polyclonal and monoclonal and those made by... |
| Using Antibodies: A Laboratory Manual by Ed Harlow, David Lane Harvard Medical School, Boston, MA. Introductory textbook for molecular biologists and other nonspecialists. Two-tone format. Previous edition: c1988. Includes nine laminated sheets entitled: Portable Protocols. Hardcover, spiral also... | |
 | Making and Using Antibodies: A Practical Handbook Antibodies are an indispensable tool in the study of biology and medicine. Making and Using Antibodies: A Practical Handbook presents techniques in a single, comprehensive source for the production and use of antibodies. It enables researchers to immediately access lab-tested, proven protocols. Written and edited by an elite team of scientists, who have developed and refined many of the... |
 | Therapeutic Antibodies (Handbook of Experimental Pharmacology) (Handbook of Experimental Pharmacology) Antibody therapeutics are the treatment of choice for several autoimmune and oncological conditions and are becoming the molecules of choice for further combination therapies and cell engineering. Current developments and clinical successes are summarized by experts in the drug development field. A must read for immunologists, clinical scientists and novel drug... |
 | Antibodies: Volume 2: Novel Technologies and Therapeutic Use If the antibody industry is to achieve its full potential in the next decade, the individual technical potentials must be exploited, the limitations must be addressed, and lessons learned must be applied both to current purification methods and to the new technologies that continue to emerge. This book presents an overview of the current advances applied in the manufacture of monoclonal antibody... |
 | Therapeutic Antibodies: Methods and Protocols (Methods in Molecular Biology) With revenues from the top five therapeutic antibodies accounting for a majority of the recent pharmaceutical sales, the research and development in the field has exploded over the past several years and is expected to grow with new emerging monoclonal antibodies like Numax, Lucentis, Actemra, and others. In Therapeutic Antibodies: Methods and Protocols, leading experts from academic laboratories... |
| © 2008 BrightSurf.com |